{
    "clinical_study": {
        "@rank": "4699", 
        "arm_group": {
            "arm_group_label": "Group 1", 
            "description": "Patients treated with Glucobay OD under practical manner"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to assess the efficacy and safety under practical use of\n      Glucobay OD. A total of 5,000 patients are to be enrolled to the study and assessed during 1\n      year observation period."
        }, 
        "brief_title": "Special Drug Use Investigation of Glucobay OD", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Glucobay OD naive diabetics. patients with at least one of the following conditions:\n             Uncontrollable with dietary therapy,exercise cure, diabetes medication, insulin\n             therapy.\n\n        Exclusion Criteria:\n\n          -  Patients who are contraindicated based on the product label"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Glucobay OD naive diabetics. Patients with at least one of the following conditions:\n        Uncontrollable with dietary therapy,exercise cure, diabetes medication, insulin therapy."
            }
        }, 
        "enrollment": {
            "#text": "2291", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01685502", 
            "org_study_id": "16517", 
            "secondary_id": "Glucobay OD"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients treated with Glucobay OD under practical manner", 
            "intervention_name": "Glucobay ODT (Acarbose, BAYG5421)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Acarbose"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Glucobay OD", 
            "Diabetes Mellitus"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Special Drug Use Investigation of Glucobay OD", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of adverse drug reactions (ADRs) and serious adverse events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "measure": "Decrease rate of HbA1c", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01685502"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Body weight", 
            "safety_issue": "No", 
            "time_frame": "up to1 year"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}